Science and Technology
We are developing novel cell therapies that combine cutting-edge iPSC technology and CRISPR-based genome editing to activate the regenerative potential of our patients’ own body and cure muscular dystrophies at their root.
We are developing novel cell therapies that combine cutting-edge iPSC technology and CRISPR-based genome editing to activate the regenerative potential of our patients’ own body and cure muscular dystrophies at their root.
.svg)
At Vita, we strive to transform the way we treat patients by addressing the root cause of their disease using truly curative cellular medicines, rather than merely treating symptoms by lifelong pharmaceutical drug regimens.
By restoring and improving tissue functions on a cellular level, we aim to refine the quality of life for patients whose medical needs are currently unmet. We are developing approaches to fix genetic defects in patient-derived stem cells and reintroduce healthy tissue generated from these cells back into the patient to restore normal function. We are also building cost-effective universal cell types that can treat all patients and bring the economies of scale to our novel cellular therapeutics.
In the autologous approach, a sample of patient blood is used to generate stem cells with nearly unlimited potential for expansion and differentiation into specialized cell types in our laboratories.
These “pluripotent” stem cells are securely banked and used to create gene-corrected healthy cells and tissues that can be reintroduced into the patient to recover biological function, support true regeneration, and cure disease at the root.
In the allogeneic approach, a “universal” iPSC line is used to generate cells and tissues needed for restoring normal biological function in patients.
These cells lines are engineered to be protected from being attacked by the patient’s immune system, allowing rapid and cost-effective treatment of currently uncurable diseases while harnessing the revolutionary potential of cellular therapy.
.svg)
Correct genetic defects
Develop universal
cells and cellular
Medicine to scale
Rebuild healthy
cells and tissues
.svg)
Unlock regeneration
Disease target is confirmed and genetic mutation(s) causing the disease are identified
Cells are isolated from a small blood draw from the patient
Blood cells are reprogrammed into iPSCs using the ‘Yamanaka’ factors
Disease-causing genetic mutations are corrected ex vivo using CRISPR technology
.svg)
.svg)
Disease target is confirmed and genetic mutation(s) causing the disease are identified
Cells are isolated from a small blood draw from the patient
Blood cells are reprogrammed into iPSCs using the ‘Yamanaka’ factors
Disease-causing genetic mutations are corrected ex vivo using CRISPR technology
Gene-corrected iPSCs are differentiated into disease-specific cell types and tissues
Healthy cells and tissues are transplanted back into the patient
Genomic and biological studies confirm suitability for developing universal cell banks
Cells are isolated from a small blood draw of the healthy donor
Healthy donor’s blood cells are reprogrammed into iPSCs using the “Yamanaka” factors
Healthy iPSCs are engineered to enable immune evasion and universal application in all patients
Universal iPSCs are differentiated into disease-specific cell types and tissues
Healthy universal cells and tissues are transplanted into patients
At Vita, we strive to transform the way we treat patients by addressing the root cause of their disease using truly curative cellular medicines, rather than merely treating symptoms by lifelong pharmaceutical drug regimens.
By restoring and improving tissue functions on a cellular level, we aim to refine the quality of life for patients whose medical needs are currently unmet. We are developing approaches to fix genetic defects in patient-derived stem cells and reintroduce healthy tissue generated from these cells back into the patient to restore normal function. We are also building cost-effective universal cell types that can treat all patients and bring the economies of scale to our novel cellular therapeutics.
Correct genetic defects
Develop universal
cells and cellular
Medicine to scale
Rebuild healthy
cells and tissues
Unlock regeneration
Disease target is confirmed and genetic mutation(s) causing the disease are identified
Cells are isolated from a small blood draw from the patient
Blood cells are reprogrammed into iPSCs using the ‘Yamanaka’ factors
Disease-causing genetic mutations are corrected ex vivo using CRISPR technology
In the autologous approach, a sample of patient blood is used to generate stem cells with nearly unlimited potential for expansion and differentiation into specialized cell types in our laboratories.
These “pluripotent” stem cells are securely banked and used to create gene-corrected healthy cells and tissues that can be reintroduced into the patient to recover biological function, support true regeneration, and cure disease at the root.
Disease target is confirmed and genetic mutation(s) causing the disease are identified
Cells are isolated from a small blood draw from the patient
Blood cells are reprogrammed into iPSCs using the ‘Yamanaka’ factors
Disease-causing genetic mutations are corrected ex vivo using CRISPR technology
Gene-corrected iPSCs are differentiated into disease-specific cell types and tissues
Healthy cells and tissues are transplanted back into the patient
In the allogeneic approach, a “universal” iPSC line is used to generate cells and tissues needed for restoring normal biological function in patients.
These cells lines are engineered to be protected from being attacked by the patient’s immune system, allowing rapid and cost-effective treatment of currently uncurable diseases while harnessing the revolutionary potential of cellular therapy.
Genomic and biological studies confirm suitability for developing universal cell banks
Cells are isolated from a small blood draw of the healthy donor
Healthy donor’s blood cells are reprogrammed into iPSCs using the “Yamanaka” factors
Healthy iPSCs are engineered to enable immune evasion and universal application in all patients
Universal iPSCs are differentiated into disease-specific cell types and tissues
Healthy universal cells and tissues are transplanted into patients
.svg){kind=logo}
